<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450385</url>
  </required_header>
  <id_info>
    <org_study_id>20061138</org_study_id>
    <secondary_id>SCCC-2006069</secondary_id>
    <secondary_id>WIRB-20070073</secondary_id>
    <nct_id>NCT00450385</nct_id>
  </id_info>
  <brief_title>Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)</brief_title>
  <acronym>R-CHOP</acronym>
  <official_title>Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that survival of newly diagnosed DLBCL (diffuse large B-cell
      lymphoma) patients treated with R-CHOP can be predicted by RNA or protein gene expression or
      by presence of biomarkers associated with the anti-tumor effects of Rituximab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase II multi-institutional trial, the investigators will identify genes associated
      with either good or bad outcome in DLBCL patients treated with R-CHOP, will construct a
      robust predictive models based on RNA extracted from or paraffin specimens as well on
      immunohistochemistry and will examine the predictive power of new biomarkers associated with
      the anti-tumor effects of rituximab. The acquisition of fixed tissue as a component of this
      uniformly treated prospective study will also afford future studies with this informative
      dataset.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator Decision due to insufficient accrual.
  </why_stopped>
  <start_date type="Actual">April 24, 2007</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of a List of Genes and Construction of Survival Prediction Models That Will Predict Overall Survival at 30 Months in DLBCL Patients Receiving R-CHOP Therapy.</measure>
    <time_frame>30 months</time_frame>
    <description>The investigators aim to determine a list of genes and construct survival prediction model(s) that will predict the overall survival at 30 months in DLBCL patients prospectively treated with R-CHOP chemotherapy. Overall survival time will be calculated from the date of the diagnosis until death or last follow-up examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Usefulness of Biomarkers Associated With Anti-Tumor Effects of Rituximab in Predicting Overall Survival in DLBCL Patients Receiving R-CHOP Therapy</measure>
    <time_frame>24 Months</time_frame>
    <description>The investigators aim to determine the usefulness of biomarkers associated with the antitumor effects of rituximab (e.g. immunoglobulin GFc receptor genotypes, CD20 protein expression and gene expression profiles) to predict overall survival of DLBCL patients treated with R-CHOP therapy and followed for at least 24 months or until death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the Ability of Constructed Survival Models to Predict Overall Survival in DLBCL Patients Receiving R-CHOP Therapy</measure>
    <time_frame>2 Years</time_frame>
    <description>The investigators will compare the ability of constructed survival models to predict survival in DLBCL patients receiving R-CHOP therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the Ability of Models and/or Biomarkers Associated With Anti-Tumor Effects of Rituximab to Predict 24-month Time to Treatment Failure in DLBCL Patients Receiving R-CHOP Therapy</measure>
    <time_frame>24 Months</time_frame>
    <description>The investigators aim to determine the ability of the models and/or biomarkers associated with the anti-tumor effects of rituximab to predict 24-month time to treatment failure, defined as disease progression, death or initiation of new treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate of Study Participants at the End of Protocol Therapy</measure>
    <time_frame>Up to 8 cycles, about 24 weeks</time_frame>
    <description>Rate of participants achieving complete response (CR), complete response/unconfirmed (CRu) partial response (PR) according to Non-Hodgkin's Lymphoma response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants From Whom Fixed Tissue Samples Were Collected for Future Studies.</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of participants from whom paraffin-embedded DLBCL tissue samples were collected for future studies.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive R-CHOP for 6 to 8 cycles:
Rituximab 375 mg/m2 on day 1
Cyclophosphamide 750 mg/m2 IV on day 1
Doxorubicin 50 mg/m2 on day 1
Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1
Prednisone 100 mg orally days 1-5, repeated every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <other_name>Deltasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Diagnosis of diffuse large B-cell lymphoma, CD20-positive, according to the World
             Health Organization Classification, stages II-IV or limited stage I disease that is
             bulky (more than 10 cm) or with International Prognostic Index (IPI) score &gt; 1.

          -  2. Patients must not have had prior chemotherapy, radiotherapy or immunotherapy. A
             short course (&lt; 2 weeks) of corticosteroids is allowed.

          -  3. Adequate paraffin-embedded tumor specimen must be available for gene expression
             analysis and immunohistochemistry prior to initiation of therapy. (If the specimen is
             deemed inadequate, the subject can be retroactively screen failed, as this does not
             change the treatment regimen).

          -  4. Baseline measurements and evaluation must be obtained within 4 weeks before first
             treatment.

          -  5. Age &gt;18 years.

          -  6. Eastern Cooperative Oncology Group (ECOG) performance status 0-3.

          -  7. Adequate organ function:

               -  White Blood Cells count (WBC) &gt;2500/µL

               -  Absolute Neutrophil Count (ANC) &gt; 1000/µL (unless due to disease in marrow)

               -  platelet count &gt;100,000/µL (unless due to disease in marrow)

               -  creatinine &lt; 2.0 mg/dL,

               -  bilirubin &lt; 1.5 mg/dL (may be 1.5-3.0 mg/dl if due to liver involvement by
                  lymphoma)

               -  Serum Glutamic Oxaloacetic Transaminase (SGOT)/ Serum Glutamic Pyruvic
                  Transaminase (SGPT) &lt;3 x upper limit of normal.

          -  8. Female patients must not be pregnant or breast feeding.

          -  9. Women of childbearing potential and men must be strongly advised to use an accepted
             and effective method of contraception.

          -  10. Patients must have left ventricular ejection fraction of &gt;45%.

          -  11. Provision of written informed consent.

        Exclusion Criteria:

          -  1. Patients with a second malignancy other than basal cell carcinoma of the skin or in
             situ carcinoma of the cervix unless the tumor was treated with curative intent at
             least two years previously; and; the patient continue to be free of evidence of
             recurrence.

          -  2. Patients with HIV infection as these patients are managed on dedicated protocols.

          -  3. Patients with active central nervous system (CNS) lymphoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Izidore S. Lossos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center - Wilmot Cancer Institute</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <results_first_submitted>March 13, 2017</results_first_submitted>
  <results_first_submitted_qc>June 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2017</results_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Izidore Lossos</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 60 patients were consented, however, only 57 of these patients were found to be eligible for enrollment per the protocol.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>R-CHOP</title>
          <description>Patients will receive R-CHOP for 6 to 8 cycles:
Rituximab 375 mg/m2 on day 1
Cyclophosphamide 750 mg/m2 IV on day 1
Doxorubicin 50 mg/m2 on day 1
Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1
Prednisone 100 mg orally days 1-5, repeated every 21 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>R-CHOP</title>
          <description>Patients will receive R-CHOP for 6 to 8 cycles:
Rituximab 375 mg/m2 on day 1
Cyclophosphamide 750 mg/m2 IV on day 1
Doxorubicin 50 mg/m2 on day 1
Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1
Prednisone 100 mg orally days 1-5, repeated every 21 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determination of a List of Genes and Construction of Survival Prediction Models That Will Predict Overall Survival at 30 Months in DLBCL Patients Receiving R-CHOP Therapy.</title>
        <description>The investigators aim to determine a list of genes and construct survival prediction model(s) that will predict the overall survival at 30 months in DLBCL patients prospectively treated with R-CHOP chemotherapy. Overall survival time will be calculated from the date of the diagnosis until death or last follow-up examination.</description>
        <time_frame>30 months</time_frame>
        <population>The study required a minimum of 90 participants for gene expression analyses from which survival prediction model(s) could be derived. Due to actual participant accrual (57) being far below the minimum number of participants required, no data were collected on gene expression, and no survival prediction models were constructed.</population>
        <group_list>
          <group group_id="O1">
            <title>R-CHOP</title>
            <description>Patients will receive R-CHOP for 6 to 8 cycles:
Rituximab 375 mg/m2 on day 1
Cyclophosphamide 750 mg/m2 IV on day 1
Doxorubicin 50 mg/m2 on day 1
Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1
Prednisone 100 mg orally days 1-5, repeated every 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of a List of Genes and Construction of Survival Prediction Models That Will Predict Overall Survival at 30 Months in DLBCL Patients Receiving R-CHOP Therapy.</title>
          <description>The investigators aim to determine a list of genes and construct survival prediction model(s) that will predict the overall survival at 30 months in DLBCL patients prospectively treated with R-CHOP chemotherapy. Overall survival time will be calculated from the date of the diagnosis until death or last follow-up examination.</description>
          <population>The study required a minimum of 90 participants for gene expression analyses from which survival prediction model(s) could be derived. Due to actual participant accrual (57) being far below the minimum number of participants required, no data were collected on gene expression, and no survival prediction models were constructed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Usefulness of Biomarkers Associated With Anti-Tumor Effects of Rituximab in Predicting Overall Survival in DLBCL Patients Receiving R-CHOP Therapy</title>
        <description>The investigators aim to determine the usefulness of biomarkers associated with the antitumor effects of rituximab (e.g. immunoglobulin GFc receptor genotypes, CD20 protein expression and gene expression profiles) to predict overall survival of DLBCL patients treated with R-CHOP therapy and followed for at least 24 months or until death.</description>
        <time_frame>24 Months</time_frame>
        <population>The study required a minimum of 90 participants for associated biomarker analyses. Due to actual participant accrual (57) being far below the minimum number of participants required, no biomarker data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>R-CHOP</title>
            <description>Patients will receive R-CHOP for 6 to 8 cycles:
Rituximab 375 mg/m2 on day 1
Cyclophosphamide 750 mg/m2 IV on day 1
Doxorubicin 50 mg/m2 on day 1
Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1
Prednisone 100 mg orally days 1-5, repeated every 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Usefulness of Biomarkers Associated With Anti-Tumor Effects of Rituximab in Predicting Overall Survival in DLBCL Patients Receiving R-CHOP Therapy</title>
          <description>The investigators aim to determine the usefulness of biomarkers associated with the antitumor effects of rituximab (e.g. immunoglobulin GFc receptor genotypes, CD20 protein expression and gene expression profiles) to predict overall survival of DLBCL patients treated with R-CHOP therapy and followed for at least 24 months or until death.</description>
          <population>The study required a minimum of 90 participants for associated biomarker analyses. Due to actual participant accrual (57) being far below the minimum number of participants required, no biomarker data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of the Ability of Constructed Survival Models to Predict Overall Survival in DLBCL Patients Receiving R-CHOP Therapy</title>
        <description>The investigators will compare the ability of constructed survival models to predict survival in DLBCL patients receiving R-CHOP therapy</description>
        <time_frame>2 Years</time_frame>
        <population>The comparison could not be made because the study required a minimum of 90 participants for initial gene expression analyses from which survival prediction model(s) would be derived. Due to actual participant accrual (57) being far below the minimum number of participants required, no gene expression or survival prediction data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>R-CHOP</title>
            <description>Patients will receive R-CHOP for 6 to 8 cycles:
Rituximab 375 mg/m2 on day 1
Cyclophosphamide 750 mg/m2 IV on day 1
Doxorubicin 50 mg/m2 on day 1
Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1
Prednisone 100 mg orally days 1-5, repeated every 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Ability of Constructed Survival Models to Predict Overall Survival in DLBCL Patients Receiving R-CHOP Therapy</title>
          <description>The investigators will compare the ability of constructed survival models to predict survival in DLBCL patients receiving R-CHOP therapy</description>
          <population>The comparison could not be made because the study required a minimum of 90 participants for initial gene expression analyses from which survival prediction model(s) would be derived. Due to actual participant accrual (57) being far below the minimum number of participants required, no gene expression or survival prediction data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determination of the Ability of Models and/or Biomarkers Associated With Anti-Tumor Effects of Rituximab to Predict 24-month Time to Treatment Failure in DLBCL Patients Receiving R-CHOP Therapy</title>
        <description>The investigators aim to determine the ability of the models and/or biomarkers associated with the anti-tumor effects of rituximab to predict 24-month time to treatment failure, defined as disease progression, death or initiation of new treatment.</description>
        <time_frame>24 Months</time_frame>
        <population>The determination could not be made because the study required a minimum of 90 participants for biomarker analyses and derivation of survival prediction model(s). Due to actual participant accrual (57) being far below the minimum required, no data were collected on the ability of models and/or biomarkers to predict time to treatment failure.</population>
        <group_list>
          <group group_id="O1">
            <title>R-CHOP</title>
            <description>Patients will receive R-CHOP for 6 to 8 cycles:
Rituximab 375 mg/m2 on day 1
Cyclophosphamide 750 mg/m2 IV on day 1
Doxorubicin 50 mg/m2 on day 1
Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1
Prednisone 100 mg orally days 1-5, repeated every 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of the Ability of Models and/or Biomarkers Associated With Anti-Tumor Effects of Rituximab to Predict 24-month Time to Treatment Failure in DLBCL Patients Receiving R-CHOP Therapy</title>
          <description>The investigators aim to determine the ability of the models and/or biomarkers associated with the anti-tumor effects of rituximab to predict 24-month time to treatment failure, defined as disease progression, death or initiation of new treatment.</description>
          <population>The determination could not be made because the study required a minimum of 90 participants for biomarker analyses and derivation of survival prediction model(s). Due to actual participant accrual (57) being far below the minimum required, no data were collected on the ability of models and/or biomarkers to predict time to treatment failure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate of Study Participants at the End of Protocol Therapy</title>
        <description>Rate of participants achieving complete response (CR), complete response/unconfirmed (CRu) partial response (PR) according to Non-Hodgkin's Lymphoma response criteria.</description>
        <time_frame>Up to 8 cycles, about 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-CHOP</title>
            <description>Patients will receive R-CHOP for 6 to 8 cycles:
Rituximab 375 mg/m2 on day 1
Cyclophosphamide 750 mg/m2 IV on day 1
Doxorubicin 50 mg/m2 on day 1
Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1
Prednisone 100 mg orally days 1-5, repeated every 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate of Study Participants at the End of Protocol Therapy</title>
          <description>Rate of participants achieving complete response (CR), complete response/unconfirmed (CRu) partial response (PR) according to Non-Hodgkin's Lymphoma response criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Complete Response unconfirmed (CRu)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants From Whom Fixed Tissue Samples Were Collected for Future Studies.</title>
        <description>Number of participants from whom paraffin-embedded DLBCL tissue samples were collected for future studies.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-CHOP</title>
            <description>Patients will receive R-CHOP for 6 to 8 cycles:
Rituximab 375 mg/m2 on day 1
Cyclophosphamide 750 mg/m2 IV on day 1
Doxorubicin 50 mg/m2 on day 1
Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1
Prednisone 100 mg orally days 1-5, repeated every 21 days.
Rituximab: Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles
Cyclophosphamide: Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
Doxorubicin: Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
Prednisone: Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.
Vincristine: Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants From Whom Fixed Tissue Samples Were Collected for Future Studies.</title>
          <description>Number of participants from whom paraffin-embedded DLBCL tissue samples were collected for future studies.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>R-CHOP</title>
          <description>Patients will receive R-CHOP for 6 to 8 cycles:
Rituximab 375 mg/m2 on day 1
Cyclophosphamide 750 mg/m2 IV on day 1
Doxorubicin 50 mg/m2 on day 1
Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1
Prednisone 100 mg orally days 1-5, repeated every 21 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Baseline adverse event</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>Baseline adverse event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cholesterol, serum-high (hypercholestremia)</sub_title>
                <description>Baseline adverse event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Uric acid, serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Baseline adverse event</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Baseline adverse event</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <description>Baseline adverse event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Baseline adverse event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Izidore Lossos MD</name_or_title>
      <organization>University of Miami</organization>
      <phone>305-243-4785</phone>
      <email>ilossos@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

